Antibody can prevent COVID-19 infection in nursing, LTC homes: drugmaker Eli Lilly

INDIANAPOLIS (AP) — Drugmaker Eli Lilly said Thursday its antibody drug can prevent COVID-19 illness in residents and staff of nursing homes and other long-term care locations.

It’s the first major study to show such a treatment may prevent illness in a group that has been devastated by the pandemic.

Residents and staff who got the drug had up to a 57 per cent lower risk of getting COVID-19 compared to others at the same facility who got a placebo, the drugmaker said. Among nursing home residents only, the risk was reduced by up to 80 per cent.

The study involved more than 1,000 residents and staff at nursing homes and other long-term care locations like assisted living homes. The vast majority tested negative at the start of the study. Some were assigned to get the drug, called bamlanivimab and which is given through an IV, and others got placebo infusions.

The research was conducted with the National Institutes of Health. Results were released in a press release, and the company said it would publish more details in a journal soon.

0:59 Coronavirus: Trudeau announces deal to obtain therapeutic drug from Eli Lilly

Among the nearly 300 residents who did not have COVID-19, four later got the disease and died. Lilly said all of them had received the placebo.

The Food and Drug Administration in November allowed emergency use of Lilly antibody drug as a treatment for people ages 12 and older with mild or moderate cases of COVID-19 that do not require hospitalization. It’s a one-time treatment.

Lilly said it plans to work with regulators to see about expanding the authorization to prevent and treat COVID-19 in long-term care facilities, where vaccinations are already underway.

Experts have said drugs like Lilly’s could serve as a bridge to help manage the virus until vaccines are widely available.

In November, Prime Minister Justin Trudeau announced Canada had purchased 26,000 doses of the therapeutic drug, with shipments to arrive between December 2020 and February 2021.

“This treatment was developed in partnership with Vancouver’s AbCellera Biologics and is part of our support for researchers right here at home who are working around the clock to find a treatment for COVID-19,” said Trudeau in a press conference then.

According to him, there would be options to secure “thousands” more doses of the drug.

Nursing homes and other long-term care locations have been hard hit by the pandemic. In the United States, they account for less than 1 per cent of the population, but nearly 40 per cent of deaths from COVID-19.

These long-term care locations have been given priority to vaccinate residents and staff with recently authorized COVID-19 vaccines. Vaccinations started last month at locations around the country.

The two vaccines approved for emergency use by Pfizer and Moderna require two doses. Major drugstore chains CVS and Walgreens are giving the shots at nursing homes in nearly all states.

0:40 Coronavirus: WHO says Remdesivir not effective in preventing death from COVID-19, trial to assess other antibodies

The companies said they expect to finish giving first doses in nursing homes this month. Their vaccination programs in nursing homes are expected to largely wrap up in February and March. Progress has been slower at other long-term locations like assisted living, where residents require less medical care than those at nursing homes.

There will still be a need for Lilly’s drug in places like nursing homes even though vaccines are already being distributed there, said WBB Securities President Steve Brozak, who follows the pharmaceutical industry.

But Brozak questioned how long the treatment might be effective with new variants of the virus popping up.

— With files from Global News